Lilly backs $45M investment for mRNA cancer immunotherapy startup


Strand Therapeutics is one step closer to realizing its ambitions for an mRNA-based cancer drug with an extension to its Series A round.

Previous AstraZeneca acquires rights to potential COPD treatment in deal valued at up to $402M
Next Why you should consider digital health care as part of your workforce strategy